EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

BACKGROUND: Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. There is therefore a need to identify biomarkers that accurately predict the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Qiufan, Hong, Shaodong, Huang, Yan, Zhao, Hongyun, Yang, Yunpeng, Hou, Xue, Zhao, Yuanyuan, Ma, Yuxiang, Zhou, Ting, Zhang, Yaxiong, Fang, Wenfeng, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026329/
https://www.ncbi.nlm.nih.gov/pubmed/32067121
http://dx.doi.org/10.1186/s40169-020-0269-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026329/
https://www.ncbi.nlm.nih.gov/pubmed/32067121
http://dx.doi.org/10.1186/s40169-020-0269-y

Ejemplares similares